Roche Changes Its Tune On 2025 Xolair Biosimilars Amid Celltrion’s First Filing
Swiss Originator Challenged Several Times On Updated Timing For Blockbuster Competition
Biosimilar competition to Xolair, one of the largest monoclonal antibodies coming off patent in the middle of this decade, has been pushed back to an unknown date in the US, as Celltrion awaits news from the US FDA on its biosimilar application.
